Accarent Health has expanded their bundled offering to include a Centers of Excellence network with focus on cellular and gene therapies, offering bundled prices for treatment through high-quality and specialized academic medical centers.
The human body is made up of trillions of cells, in which thousands of genes live and support the production of proteins and enzymes to make muscles, bones, and blood. Proper functioning of these genetic systems supports our body’s functions, down to the most crucial tasks of producing energy and growth. If all or part of a gene is defective, missing, or mutates over time, protein production will be disrupted, causing health problems and disease. 
With gene therapies, scientists can genetically engineer defective or missing genes by replacing, disabling, or adding genes to help the body properly function or fight disease. Gene Therapies are changing medicine and providing solutions for previously incurable or life-altering conditions. 
It is estimated that 95,000 individuals will be eligible for gene or cell therapy by 2025. And with the cost of these therapies 30x the median household income, it is expected to cost payers an estimated $25B by 2026. Gene Therapy is already having an enormous financial impact on employer-sponsored health care today. As payers consider the future risk with the approval of additional high-cost therapies, many seek new approaches to address the multiple facets of gene and cell therapies. 
The Accarent Health cellular and gene therapy program aims to help organizations prepare, manage, and reduce the financial impact of these exceptional therapeutics, through bundled pricing, beginning with CAR-T and other gene therapies that focus on treating:
- B Cell Lymphoma
- Mantel Cell Lymphoma
- Acute Lymphocytic Leukemia
- Spinal Muscular Atrophy
- Retinal Dystrophy
Through Accarent Health, employers, patients, and plan administrators are connected to a network of top-rated medical centers for a range of specialty care procedures and treatments at no annual membership fees or volume requirement. Accarent’s platform with defined episodes of care, transparent bundled pricing, pertinent clinical information, travel, and concierge assistance makes value-based healthcare understandable for the decision maker.
Employers and intermediaries interested in adopting a value-based health care strategy can learn more about Accarent Health at www.accarenthealth.com.
 US Food and Drug Administration. July 25th, 2018. What is Gene Therapy? How Does it Work? https://www.fda.gov/consumers/consumer-updates/what-gene-therapy-how-does-it-work. October 2021.
 Chi Heem Wong, Dexin Li, Nina Wang, Jonathan Gruber, Rena Conti, Andrew W. Lo. Estimating the Financial Impact of Gene Therapy.https://www.medrxiv.org/content/10.1101/2020.10.27.20220871v1.full